Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression - Concepedia

Concepedia

Publication | Open Access

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

DOI Full Paper Access

107

Citations

30

References

2020

Year

Irene Y. Cheung, Nai‐Kong V. Cheung, Shakeel Modak, Audrey Mauguen, Yi Feng, Ellen M. Basu, Stephen S. Roberts, Govind Ragupathi, Brian H. Kushner

Journal of Clinical Oncology

Abstract

GD2/GD3 vaccine plus β-glucan elicited robust antibody responses in patients with HR-NB with prior PD. Higher anti-GD2-IgG1 titer was associated with improved survival.

References

	Year	Citations

Page 1